Justify residue acceptance limits
Carryover limits require toxicological justification and consideration of equipment trains.
CV-REQ-000002
EU GMP Annex 15: Qualification and Validation§ 10.6
TOPIC EXPLORER
HBEL & PDE
Health-based exposure limits and their role in cross-contamination risk assessment.
5 connected references
Establish and reassess HBELs
Establish HBELs for medicinal products and reassess supporting data periodically.
CV-REQ-000020
HBEL and cross-contamination: questions and answers§ Q1
Qualify the HBEL assessor
HBEL development requires suitable toxicological and pharmacological expertise.
CV-REQ-000021
HBEL and cross-contamination: questions and answers§ Q4
Distinguish HBELs from cleaning alert limits
An HBEL is not automatically the operational cleaning limit.
CV-REQ-000022
HBEL and cross-contamination: questions and answers§ Q6
Use HBELs within risk assessment
HBEL implementation supports assessment of cross-contamination controls.
CV-REQ-000029
Cross-contamination control and HBEL Q&As§ Inspectorate commentary — HBEL implementation
Practical guidance
From Biologics to ADCs: Why New Modalities Are Changing Cleaning Validation
Biologics degrade under cleaning, ADCs split one residue into antibody, linker, payload and conjugate, and peptide APIs combine high potency with methods already under strain. A synthesis of the local evidence on why toxicology, cleaning and detectability now move together.
A MACO Is Only as Good as the Assumptions Behind It
A maximum allowable carry-over value is a PDE multiplied by a set of process assumptions — batch size, dose, surface area, recovery and the cleaning step itself. Read as a body of evidence, the 2025–2026 enforcement record is rarely about toxicity assessment, and almost always about those assumptions.
PIC/S Publishes PI 006-4: A New Qualification and Validation Recommendation Takes Effect in October
PIC/S has published PI 006-4, the revised Recommendations on Qualification and Validation, superseding the 2007 PI 006-3 and entering into force on 1 October 2026. Cleaning validation now occupies a full chapter, with HBEL-driven scope, explicit limits on visual inspection and a clear position against continued test-until-clean practice.
ADCs Are Creating a New Cleaning Validation Problem
Antibody-drug conjugates combine a biologic, a chemical linker and a cytotoxic payload on shared equipment. A STERIS webinar frames the problem; independent guidance shows why one product-specific assay no longer answers the question.
Peptide APIs Put Cleaning Limits Under the Microscope: FDA Cites Missing MACO for Semaglutide and Tirzepatide
FDA's 1 May 2026 warning letter to Harbin Jixianglong Biotech found a cleaning procedure that required a toxicity-based carryover limit, and a validation study that established none — with no justification for swab locations and no swab results.
Worst Case or Product-Specific? New Research Reopens the Cleaning Validation Strategy Debate
A comparative review in the PDA Journal weighs worst-case matrices against product-specific validation and proposes a hybrid model anchored on visible residue limits.
ASTM Updates Its HBEL Guide: What E3219-25 Means for Cleaning Validation
ASTM has re-issued E3219 as E3219-25, the current reference for deriving health-based exposure limits. HBELs are a decade-old regulatory expectation, not a 2025 novelty — but the revision sharpens how limits are derived, documented and defended.
Do Cleaning Validation Programmes Need Every Analytical Test They Currently Run?
A lightning talk at PDA Week 2025 argued for a lean approach to analytical panels in cleaning validation. The independent framework to justify it already exists in ASTM E3106 and ICH Q9(R1) — but only if the arithmetic is documented.
What Happens to Biologics During Cleaning? New Data on Cleaning-Induced Protein Degradants
A bench-scale study puts the 650 ug/dose parenteral PDE for cleaning-induced protein degradants to the test with human-cell immunogenicity assays on HLE BiTE and mAb degradants, spiked into the same and a cross product.